Specify a stock or a cryptocurrency in the search bar to get a summary
Medlive Technology Co Ltd
2192Medlive Technology Co., Ltd. operates an online professional physician platform in Mainland China and internationally. The company's precision marketing and corporate solution provides digital marketing, digital detailing, digital marketing consultation, digital content creation, application software development, and other relevant services. Its medical knowledge solution offers medical education and clinical decision support, including licensing software to physicians, other registered users, such as other healthcare professionals and pharmaceutical companies. The company's intelligent patient management solution provides single disease management services, including diseases knowledge dissemination and treatment compliance monitoring management; patient education services comprising content development, application software development, and other related services; and chronic disease management services for Parkinson's lymphoma, stroke and diabetes, and breast, lung, and ovarian cancer. In addition, it is involved in research and development services; internet hospital services; publication and planning services for medicine guidelines and medical consensus; organizing medical exhibition conferences; provision of medical services; and research services to pharmaceutical companies. The company was formerly known as Kingyee Co., Limited and changed its name to Medlive Technology Co., Ltd. in 2021. The company was founded in 1996 and is headquartered in Beijing, China. Address: Red Mnr Intl. Bonded Innovation Park, Beijing, China
Analytics
WallStreet Target Price
83.93 HKDP/E ratio
21.1628Dividend Yield
2.97 %Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures 2192
Dividend Analytics 2192
Dividend growth over 5 years
–Continuous growth
1 yearPayout Ratio 5 years average
33 %Dividend History 2192
Stock Valuation 2192
Financials 2192
Results | 2019 | Dynamics |